33 results about "RNA Aptamers" patented technology

In vitro SELEX has been used to discover high affinity RNA aptamers interacting with the tetracycline repressor protein in a tetracycline-dependent manner. Using in silico RNA folding predictions to guide the design of both aptamer truncations and mutants, minimized tetracycline repressor protein high affinity binding aptamers have been defined. Using one such aptamer, inducible post-transcriptional regulation in vivo has been demonstrated that is predicated on a direct interaction between a tetracycline repressor protein and a RNA aptamer element. These aptamer components can be integrated in any organism to inducibly regulate RNA translation of a gene of interest.

The present invention describes methods for the production and use of single chain (single-stranded) fluorescence resonance energy transfer (“FRET”) DNA or RNA aptamers containing fluorophores (F) and quenchers (Q) at various loci within their structures, such that when its specific matching analyte is bound and the FRET-aptamers are excited by specific wavelengths of light, the fluorescence intensity of the system is modulated (increased or decreased) in proportion to the amount of analyte added. F and Q are covalently linked to nucleotide triphosphates (NTPs), which are incorporated by various nucleic acid polymerases such as Taq polymerase during the polymerase chain reaction (PCR) and then selected by affinity chromatographic, size-exclusion or molecular sieving, and fluorescence techniques. Further separation of related FRET-aptamers can be achieved by ion-pair reverse phase high performance liquid chromatography (HPLC) or other types of chromatography. Finally, FRET-aptamer structures and the specific locations of F and Q within FRET-aptamer structures are determined by digestion with exonucleases and mass spectral nucleotide sequencing analysis.

RNA molecules are an important member of an intracellular genetic information delivery system. Conventional RNA labeling methods cannot simultaneously have the characteristics of living cells, no invasion, high temporal and spatial resolution, single molecules, etc., so a novel method for labeling and tracking RNA need to be developed. The invention discloses a novel labeling method for messengerRNA and circular RNA based on self-ligation label bimolecular fluorescence complementation. A RNA aptamer subsystem is cooperatively used, aptamers are inserted at proper positions in the RNA, and twoparts of a self-ligation label are respectively fused with the binding proteins of the RNA aptamers. When the fusion proteins do not bind to RNA, RNA molecules do not fluoresce; when and only when the fusion proteins bind to RNA, the RNA molecules fluoresce, so the fluorescence background of an intracellular RNA marker is reduced. The novel RNA labeling method based on self-ligation label bimolecular fluorescence complementation can be used for long-term interference-free single-molecule imaging observation and tracking of messenger RNA and circular RNA of living cells and fixed cells, and has good application prospects in cell biology.

The present invention describes methods for the production and use of single chain (single-stranded) fluorescence resonance energy transfer (“FRET”) DNA or RNA aptamers containing fluorophores (F) and quenchers (Q) at various loci within their structures, such that when its specific matching analyte is bound and the FRET-aptamers are excited by specific wavelengths of light, the fluorescence intensity of the system is modulated (increased or decreased) in proportion to the amount of analyte added. F and Q are covalently linked to nucleotide triphosphates (NTPs), which are incorporated by various nucleic acid polymerases such as Taq polymerase during the polymerase chain reaction (PCR) and then selected by affinity chromatographic, size-exclusion or molecular sieving, and fluorescence techniques. Further separation of related FRET-aptamers can be achieved by ion-pair reverse phase high performance liquid chromatography (HPLC) or other types of chromatography. Finally, FRET-aptamer structures and the specific locations of F and Q within FRET-aptamer structures are determined by digestion with exonucleases and mass spectral nucleotide sequencing analysis.

Provided herein, inter alia, are compounds capable of binding HSP70 (e.g. mHSP70) on a cell and internalizing into said cell. The compositions provided herein may be useful for delivering therapeutic and diagnostic agents to a cell. Further provided are pharmaceutical compositions and methods of treatment using nucleic acid compounds provided herein.

The present invention relates to methods of using cocaine-binding-site ligands and cocaine-binding-site RNA aptamers to treat or prevent Alzheimer's Disease and to reduce or prevent aggregation of beta-amyloid peptides in a subject.

Nuclease-resistant RNA aptamers are provided which are capable of neutralizing PDGFRβ and are therefore useful in the diagnosis and / or therapy of PDGFRβ-associated and hyperproliferative-associated diseases, such as cancer and primary tumour metastasis. RNA aptamers provided herein include a modified synthetic RNA sequence wherein at least one pyrimidine residue is modified to 2′-fluoropyrimidine. Pharmaceutical compositions and diagnostic kits comprising RNA aptamers are also provided.

The present disclosure relates to RNA aptamers and uses thereof, in particular, aptamers which specifically bind to CD133 and which demonstrate superior tumor penetration.

Nuclease-resistant RNA aptamers are provided which are capable of neutralizing PDGFRβ and are therefore useful in the diagnosis and / or therapy of PDGFRβ-associated and hyperproliferative-associated diseases, such as cancer and primary tumor metastasis. RNA aptamers provided herein include a modified synthetic RNA sequence wherein at least one pyrimidine residue is modified to 2′-fluoropyrimidine. Pharmaceutical compositions and diagnostic kits comprising RNA aptamers are also provided.

The present invention provides methods of treatment using inhibitors of DEK protein and DEK activity. Such methods include, but are not limited to, methods of preventing, treating, and / or ameliorating inflammatory diseases, infections, autoimmune diseases, malignant diseases, and other diseases or conditions in which DEK has been implicated. Such inhibitors of DEK protein include, but are not limited to, pharmaceutical compositions including single stranded DNA or RNA aptamers capable of binding to DEK. In some embodiments, such aptamers are useful for diagnosing DEK related diseases or conditions. Related kits and compositions are further provided.

Provided are chemically modified ribonucleic acid (RNA) aptamers comprising one or more of 2′F guanylate, 2′OMe cytidylate, 2′OMe adenylate, and a deoxy pyrimidine nucleotide with a moiety on the 5 position of the pyrimidine; and methods of making the aptamers.

Disclosed is an RNA aptamer, a synthetic oligonucleotide of 2′-fluoro-modified A, U, and C nucleotides, with improved stability compared to its unmodified counterpart. Like the unmodified aptamer, however, the modified version is a potent glutamate receptor antagonist. Additionally, the RNA aptamers described herein are water soluble by nature, and generally exhibit nano- to micromolar potency making them potential therapeutic agents for the treatment of neurological disorders involving glutamate receptor activity.

The invention relates to a magnetic fluorescent copolymer nano probe taking DNA (deoxyribonucleic acid) as a template. The probe comprises a linear template DNA chain, wherein the template DNA chain is connected with magnetic nano particles with superparamagnetism, quantum dot nano particles with fluorescence and DNA or RNA (ribonucleic acid) aptamers capable of specifically identifying a tumor cell by identifying a DNA sequence; and the magnetic nano particles or the quantum dot nano particles and the DNA or RNA aptamers are alternately connected onto the template DNA chain. The invention further discloses an application of the magnetic fluorescent copolymer nano probe in a preparation for identifying a circulating tumor cell. The nano probe can amplify a magnetic signal and a fluorescentsignal, and has higher specific selection on tumor cells and lower non-specific absorption on normal blood cells.

This application discloses a method for detecting cellular RNA expression. According to the principle of bimolecular fluorescence complementation, different RNA binding proteins or structural domains are fused at the N-terminal and C-terminal of the fluorescent molecule, and two exogenously expressed RNA aptamers pass through The principle of complementary base pairing is combined with the RNA to be detected, and the two RNAs expressed exogenously contain RNA binding protein binding sequences, and when the two fusion expressed different RNA binding proteins bind to them, they will emit fluorescence.

The invention discloses a production method of recombinant small RNA. In the method, tRNA is used as a scaffold, and a chimeric miRNA precursor is used to express target small RNA in Escherichia coli. In addition, the invention also discloses the application of the recombinant small RNA produced by the method. The recombinant small RNA designed and prepared by the present invention is obtained through bioengineering technology, and has the advantages of simple and convenient equipment, rapid production, high yield, low cost, and good functionality; tests by various technical means show that the method of the present invention can conveniently and quickly Prepare a variety of miRNA / siRNA / RNA aptamers, and produce recombinant small RNAs to meet the needs of scientific research and drug development.

Described herein is a method that displays RNA on the DNA from which it was encoded, enabling enhanced selection of RNA aptamers and proteins. The covalent link between RNA and the DNA which encodes it can be used to negate the spatial informational loss following transcription. This method has applications in the selection of binding ligands such as RNA aptamers and antibodies as well as catalytic molecules such as aptazymes and enzymes.

The present invention relates to an aptamer or an active fragment thereof raised against the semi-conserved duffy binding ligand domain 1α, DBL1α, region of the Plasmodium falciparum erythrocyte membrane protein 1, PfEMPI, which aptamer has an effect against malaria, in particular severe cerebral malaria.

In vitro SELEX has been used to discover high affinity RNA aptamers interacting with the tetracycline repressor protein in a tetracycline-dependent manner. Using in silico RNA folding predictions to guide the design of both aptamer truncations and mutants, minimized tetracycline repressor protein high affinity binding aptamers have been defined. Using one such aptamer, inducible post-transcriptional regulation in vivo has been demonstrated that is predicated on a direct interaction between a tetracycline repressor protein and a RNA aptamer element. These aptamer components can be integrated in any organism to inducibly regulate RNA translation of a gene of interest.